QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced the launch of QIAseq Targeted cfDNA Ultra Panels that will enable researchers studying cancer ...
PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions Prometheus Biosciences&rs...
Cold Spring Harbor Laboratory Professor Adrian Krainer is best known for his groundbreaking research on antisense oligonucleotides (ASOs)—m...
The Barbara Ann Karmanos Cancer Institute, a leading breast cancer prevention and care provider, has adopted Volpara® Risk Pathways™, a market-le...
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative pre...
The research was in collaboration with the Samsung Medical Center, Sungkyunkwan University School of Medicine. This study adds to the previous studies of p...
OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data demonstrating significant synergistic effects of OBI-999 and pembrolizumab (anti-PD1 mAb) in...
Under normal circumstances, interactions between PD-1 and its ligand PD-L1 can halt or limit the immune system’s response to human cells and suppress...
Cancer is one of the leading causes of death across Asian countries. According to a report published by Janssen Asia Pacific, in 2017, overall, there wer...
Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the de...
he Phase 1, first-in-human, multicenter clinical study seeks to characterize the safety, potential efficacy and evaluate possible biomarkers of response to...
Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, ...
Nefecon NDA is currently under Priority Review in China and expected to receive approval in 2H 2023- Everest Medicines (HKEX 1952.HK, "...
The oversubscribed financing was led by Novalis LifeSciences, with participation from Sozo Ventures, Hatteras Venture Partners, iSelect Fund, American Canc...
© 2025 Biopharma Boardroom. All Rights Reserved.
